ecrin-mdr-crcClinical2013metastatic colorectal cancerMetastatic Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2646684Japan1ECRIN MDRActive, not recruitingfalseAnalysis of differentiation of antiEGFR antibody in the 1st line chemotherapy with mFOLFOX6 in RAS-wild metastatic colorectal cancer.Interventions: mFOLFOX6+cetuximab or panitumumab Primary outcome(s): response rate Study Design: Single arm Non-randomized2013-01-152646684JPRN-UMIN000031535